Advertisement
Screener

GENZYME CORP Patents: Applications Pending, 2024, Page 2

GENZYME CORP Patent Applications Pending

108 applications still open at the USPTO, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.

  • 2024-02-06: Application 63550356; Invention TREATMENT OF CANCER WITH ANTI-ILT2 ANTIBODIES; Applicant GENZYME CORPORATION; Status Provisional Application Expired.
  • 2024-02-02: Application PCTUS2024014265; Invention HSC-SPECIFIC ANTIBODY CONJUGATED LIPID NANOPARTICLES AND USES THEREOF; Applicant GENZYME CORPORATION; Status RO PROCESSING COMPLETED-PLACED IN STORAGE.
  • 2024-01-26: Application 63625856; Invention ARTIFICIAL microRNAs TARGETING SNCA; Applicant Genzyme Corporation; Status Provisional Application Expired.
  • 2024-01-26: Application 63625838; Invention ARTIFICIAL microRNAs TARGETING HUNTINGTON’S DISEASE; Applicant Genzyme Corporation; Status Provisional Application Expired.
FiledApplicationInventionApplicantStatusPublished asInventor nameInventor countryExaminer
2024-02-0663550356TREATMENT OF CANCER WITH ANTI-ILT2 ANTIBODIESGENZYME CORPORATION
BIOND BIOLOGICS LTD.
Provisional Application Expired
Dana Haves Ziv
Liat Tevel
Enas Halumi
Nyra Goldstein
Tsuri Peretz
Ilana Goldshtein
Tal Gabay
Anna Fridam-Dror
Itay Friedman
Sharon Hashmueli
Motti Hakim
Ilana Mandel
Avidor Shulman
Yair Sapir
Tehila Ben-Moshe
Giovanni Abbadessa
Meijing Wu
Nigel Patrick Somerville Crawford
Rui Wang
Maria Agarwal
Cecilia Deantonio
Raymond Perez
Ji Lin
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
Israel
United States
United States
United States
United States
United Kingdom
United States
United States
2024-02-02PCTUS2024014265HSC-SPECIFIC ANTIBODY CONJUGATED LIPID NANOPARTICLES AND USES THEREOFGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
CHRISTOPHER BORGES
AUSTIN WAYNE BOESCH
DARYL CLARK DRUMMOND
JACOB HOPE
CHRISTOPHE LECHAUVE
CHRISTIAN MUELLER
AUSTIN WAYNE BOESCH
United States
United States
United States
United States
United States
United States
United States
2024-01-2663625856ARTIFICIAL microRNAs TARGETING SNCAGenzyme CorporationProvisional Application Expired
Bradford Miller ELMER
Shyam RAMACHANDRAN
United States
United States
2024-01-2663625838ARTIFICIAL microRNAs TARGETING HUNTINGTON’S DISEASEGenzyme CorporationProvisional Application Expired
Johanna Gabrielle ADAMS
Bradford Miller ELMER
Shyam RAMACHANDRAN
Brenda Richards
United States
United States
United States
United States
2024-01-2563624935PREDICTING MOTOR FUNCTION SCORES IN POMPE DISEASE TREATMENTGenzyme CorporationProvisional Application Expired
Julie L. Batista
Kelly George
Kristina An Haack
Rana Jreich
Chanchala Kaddi
Zhaoling Meng
Catherine Ortemann-Renon
Fatiha Rachedi
Mengdi Tao
Atef Zaher
Susana Zaph
United States
United States
France
France
United States
United States
United States
France
United States
Canada
United States
2024-01-22PCTUS2024012330DRUG FORMULATIONS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL) -3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILEGENZYME CORPORATIONRO PROCESSING COMPLETED-PLACED IN STORAGE
JEROME ARIGON
MARILYN CALDERONE
BRIGITTE ILLEL
United States
United States
United States
2024-01-1818416145CONTINUOUS PRODUCTION OF RECOMBINANT PROTEINSGenzyme CorporationPublications -- Issue Fee Payment VerifiedUS20240150395A1
Michael Coolbaugh
Tarl Vetter
Chad Varner
Kevin Brower
United States
United States
United States
United States
WECKER, JENNIFER
2024-01-0818407298RECOMBINANT AAV VECTORS EXPRESSING OSTEOPROTECTIVE GENES, INCLUDING HAS2 AND LUBRICIN, USEFUL IN THE TREATMENT OF OSTEOARTHRITIS AND RELATED JOINT CONDITIONS IN MAMMALSGenzyme CorporationNon Final Action MailedUS20240254454A1
Monica DIAS FIGUEIREDO
Sirkka RM KYOSTIO-MOORE
Patricia BERTHELETTE
United States
United States
United States
NGUYEN, QUANG